Tratamiento de tumores neuroendocrinos metastáticos con 177Lu-DOTATATE
Grado en ...
openaire +1 more source
Analysis of clinical factors associated with incomplete standard protocol <sup>177</sup>Lu-DOTATATE treatment in neuroendocrine tumor patients. [PDF]
Sugawara S +6 more
europepmc +1 more source
Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient with Treatment-Related Neuroendocrine Prostate Cancer with Urinary Retention and Rectal Obstruction: A Case Report. [PDF]
Yasukawa R +5 more
europepmc +1 more source
Case of the Season: <sup>177</sup>Lu-DOTATATE Peptide Receptor Radiotherapy With Acute Dialysis Support in a Patient With Chronic Kidney Disease (CKD). [PDF]
Fitzpatrick KJ +5 more
europepmc +1 more source
Dosimetric implications of kidney anatomical volume changes in <sup>177</sup>Lu-DOTATATE therapy. [PDF]
Khan J +5 more
europepmc +1 more source
Evaluating auto-contouring accuracy in reduced CT dose images for radiopharmaceutical therapies: Denoising and evaluation of <sup>177</sup>Lu DOTATATE therapy dataset. [PDF]
Yang HT, Ko KY, Yang CC.
europepmc +1 more source
Role of <sup>18</sup>F-AlF-NOTATATE PET/CT in selecting pediatric neuroblastoma candidates for <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy. [PDF]
Liu Y +6 more
europepmc +1 more source
Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center. [PDF]
Mathew D +7 more
europepmc +1 more source
<sup>177</sup>Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods. [PDF]
Donzé C +6 more
europepmc +1 more source

